Novartis Buys Dermatology Group Fougera for $1.525 Billion

May 3, 2012
The combined businesses will become the number one global company in generic dermatology medicines, with annual global sales of nearly $620 million.

In a move that Novartis (IW 1000/71) hopes will propel the company to market leader position on generic dermatology medicines, the company announed on May 3 that it will buy dermatology generics group Fougera for $1.525 billion.

Novartis said it would pay cash for the acquisition and that Fougera will be integrated into its generic pharmaceutical division.

"The combined businesses will become the number one global company in generic dermatology medicines, with estimated annual global sales of nearly $620 million, primarily in the U.S.," said the Basel-based group.

Fougera posted sales reaching $429 million in 2011 and employs about 700 people.

Copyright Agence France-Presse, 2012

See Also
Novartis Cuts 2,000 U.S. Jobs After Patent Loss

Popular Sponsored Recommendations

Empowering the Modern Workforce: The Power of Connected Worker Technologies

March 1, 2024
Explore real-world strategies to boost worker safety, collaboration, training, and productivity in manufacturing. Emphasizing Industry 4.0, we'll discuss digitalization and automation...

3 Best Practices to Create a Product-Centric Competitive Advantage with PRO.FILE PLM

Jan. 25, 2024
Gain insight on best practices and strategies you need to accelerate engineering change management and reduce time to market. Register now for your opportunity to accelerate your...

How Manufacturers Can Optimize Operations with Weather Intelligence

Nov. 2, 2023
The bad news? Severe weather has emerged as one of the biggest threats to continuity and safety in manufacturing. The good news? The intelligence solutions that build weather ...

Transformative Capabilities for XaaS Models in Manufacturing

Feb. 14, 2024
The manufacturing sector is undergoing a pivotal shift toward "servitization," or enhancing product offerings with services and embracing a subscription model. This transition...

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!